Regadenoson induces comparable left ventricular perfusion defects as adenosine: a quantitative analysis from the ADVANCE MPI 2 trial. - Wikidata - awgldk - TriplyDB

Regadenoson induces comparable left ventricular perfusion defects as adenosine: a quantitative analysis from the ADVANCE MPI 2 trial.

Regadenoson induces comparable left ventricular perfusion defects as adenosine: a quantitative analysis from the ADVANCE MPI 2 trial.

http://www.wikidata.org/entity/Q43292397

about

Regadenoson use in patients with chronic obstructive pulmonary disease: the state of current knowledge Nuclear cardiology: 2014 innovations and developments Assessment of cardiac ischaemia and viability: role of cardiovascular magnetic resonance "Same-patient processing" for multiple cardiac SPECT studies. 2. Improving quantification repeatability.Depressive symptoms are associated with mental stress-induced myocardial ischemia after acute myocardial infarction A fast cardiac gamma camera with dynamic SPECT capabilities: design, system validation and future potential Improvement in PET myocardial perfusion image quality and quantification with flurpiridaz F 18.Automatic and visual reproducibility of perfusion and function measures for myocardial perfusion SPECT.Utility of nuclear stress imaging for detecting coronary artery bypass graft disease.Cardiac CT for myocardial ischaemia detection and characterization--comparative analysis Association between anger and mental stress-induced myocardial ischemia Angina and mental stress-induced myocardial ischemia Detection of obstructive coronary artery disease using regadenoson stress and 82Rb PET/CT myocardial perfusion imaging.EANM procedural guidelines for radionuclide myocardial perfusion imaging with SPECT and SPECT/CT: 2015 revision Quantitative analysis of perfusion studies: strengths and pitfalls Automated Quantitative Nuclear Cardiology Methods Prevalence and significance of electrocardiographic changes and side effect profile of regadenoson compared with adenosine during myocardial perfusion imaging.Regadenoson and adenosine are equivalent vasodilators and are superior than dipyridamole- a study of first pass quantitative perfusion cardiovascular magnetic resonance.Prognostic value of normal regadenoson stress perfusion cardiovascular magnetic resonance.Stress echocardiography for the detection and assessment of coronary artery disease.Selective adenosine agonists and myocardial perfusion imaging.Regadenoson: a focused update.Regadenoson for myocardial perfusion scintigraphy.Advances in SPECT in evaluating coronary disease.Serious and potentially life threatening complications of cardiac stress testing: Physiological mechanisms and management strategies.Single-scan rest/stress imaging with 99mTc-Sestamibi and cadmium zinc telluride-based SPECT for hyperemic flow quantification: A feasibility study evaluated with cardiac magnetic resonance imaging.Regadenoson stress for myocardial perfusion imaging.Regadenoson use in chronic kidney disease and end-stage renal disease: A focused review.Feasibility, safety and accuracy of regadenoson-atropine (REGAT) stress echocardiography for the diagnosis of coronary artery disease: an angiographic correlative study.Effect of changes in perfusion defect size during serial regadenoson myocardial perfusion imaging on cardiovascular outcomes in high-risk patients.Comparison of the prognostic value of regadenoson and adenosine myocardial perfusion imaging.Safety of regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic kidney disease patients not on hemodialysis.Prognostic value of regadenoson myocardial single-photon emission computed tomography in patients with different degrees of renal dysfunction.Hemodynamic response, arrhythmic risk, and overall safety of regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic obstructive pulmonary disease and bronchial asthma patients.A strategy of symptom-limited exercise with regadenoson-as-needed for stress myocardial perfusion imaging: a randomized controlled trial.Regadenoson provides perfusion results comparable to adenosine in heterogeneous patient populations: a quantitative analysis from the ADVANCE MPI trials.Comparison of hemodynamic and stress testing variables in patients undergoing regadenoson stress myocardial perfusion imaging to regadenoson with adjunctive low-level exercise myocardial perfusion imaging.Regadenoson-induced hyperemia for absolute myocardial blood flow quantitation by 13N-ammonia PET and detection of cardiac allograft vasculopathy.Noninvasive PET quantitative myocardial blood flow with regadenoson for assessing cardiac allograft vasculopathy in orthotopic heart transplantation patients.Vasodilator stress agents for myocardial perfusion imaging.

P2860

Q26829779-6A8C9499-4F14-49CF-9A57-00D1AA33052A Q28081835-FA480E7C-BEF6-448B-95E9-963EF0DBE5CD Q28387402-FAFF2A18-FE1B-4AFB-AF3B-3A35884E88C7 Q33751431-3F0F8A40-BFE6-44D0-8DDB-3A12B8204439 Q33951629-4E6CDEE0-B6BF-41F5-9D3C-2F0940798485 Q34102501-AF48D652-CB2D-4E5F-B6F5-3156816EEB4F Q34132855-687DD8F3-3A0D-465C-8470-585C5CAB3764 Q34341694-F23E3BC3-2F8C-453D-A435-C16DD41F6D71 Q34365641-3DEFFA54-AA27-4E61-8D2D-F21C4CD8BCB6 Q34392078-28C35AA8-FBD5-422D-B6FF-26B3F8EB5C78 Q34718603-99A95F5D-D386-4A5A-880F-B25C925AAEB0 Q35235615-6C4C76AA-04E5-4E56-80EC-79A26C16E072 Q35243117-1C703246-9D30-4A7F-B66C-0B498F9D379D Q36109226-BFBAF1F8-1CF7-4F30-AA45-ED2E3DD903E5 Q36142720-B7391437-77F7-487E-ADA3-F9812AC2D0AD Q36927242-994D7075-6D44-4B23-A430-E467CD688627 Q37134444-451E7CC3-B405-4B9A-9670-31FE34D6DF0A Q37364858-C9CD4470-833C-44E7-9F4A-90CCAAA1321F Q37425510-D06E857A-358E-4B88-9C34-47D9C1E57E4A Q37856914-34B6A50C-BDD6-4ADF-9267-58E8B60E321C Q37963279-8797F665-6591-4956-B786-BB8B4008F04C Q38066403-391541DC-EF7D-4B23-B321-538743F32684 Q38089891-14F701D4-A291-4D5C-90E5-E92FEE311242 Q38231506-02EF3409-D944-4896-9923-680DB49EAF23 Q38480969-1D5737C8-3E22-448D-A066-AEA76711EAF1 Q38619851-684B7875-F998-4EEF-960F-51F78C2306A4 Q38660349-B64E69F5-FEBB-4501-A0A8-5144782AE7FE Q38707736-2BF9DF29-3A4E-431D-A84A-AD674A226807 Q39264143-DD534751-728B-4BC3-94E0-553EC2C2E57F Q40896705-DBB8E951-862F-40A3-B440-5856CF0A4593 Q40925997-C933F9A2-6035-4E5C-BF98-D5F96F7309F2 Q44116521-473843A6-6F21-4D8E-9BE2-B81B80EDB500 Q44285893-872BA184-0493-4379-ABFF-13AC674D7486 Q44704119-70AA4A1E-EDD3-4090-B484-21B952AB492D Q45354603-DAB5F05A-E8DA-48C0-BDE7-1A2EF189BDC5 Q45833492-F5F46514-486E-493F-BEC1-831DEB58A47F Q46132320-AC067F05-C6B9-4470-B3CE-5B6AE8B7DBC9 Q46173006-7FE950F3-8760-42B0-81AC-D78F56BE22E3 Q46433503-3D0E6DEF-3022-4B56-ABE9-DB95DDDDCB89 Q48065022-70A61F7A-F61A-4F32-962E-B8428064BED3

P2860

Regadenoson induces comparable left ventricular perfusion defects as adenosine: a quantitative analysis from the ADVANCE MPI 2 trial.

http://www.wikidata.org/entity/Q43292397

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Regadenoson induces comparable ...... from the ADVANCE MPI 2 trial.

@en

Regadenoson induces comparable ...... from the ADVANCE MPI 2 trial.

@nl

type

label

Regadenoson induces comparable ...... from the ADVANCE MPI 2 trial.

@en

Regadenoson induces comparable ...... from the ADVANCE MPI 2 trial.

@nl

prefLabel

Regadenoson induces comparable ...... from the ADVANCE MPI 2 trial.

@en

Regadenoson induces comparable ...... from the ADVANCE MPI 2 trial.

@nl

P1433

Q43292397-DE20C867-53B7-4284-9C48-E4DE8062E05A

P1476

Q43292397-45690AB3-B158-440F-BEE4-AA25287CDEE9

P2093

Q43292397-03BD5B78-6D7F-4DEE-ADD5-F03537B8F504

Q43292397-044D9155-216C-44F8-806C-2F1A9C7DD9A3

Q43292397-0CA4C49E-F97F-4845-8BF6-46576DD520F6

Q43292397-45199EC7-7E12-4F6D-A8EF-3B4CEC47D441

Q43292397-5838195E-3D47-4A05-AB51-53B8EFF2C276

Q43292397-8314E3A4-B7A3-4B65-AC48-972BF9EBCD93

Q43292397-B0A19BD2-87E8-4E20-B79D-51C789DAAA28

Q43292397-B2756F9F-E1A8-4677-AB07-DD6511869CCD

P304

Q43292397-FCAF1A10-18B2-47AD-8441-7FA8E862FC75

P31

Q43292397-8DE009D5-3FEB-413C-85CD-5E0489E49296

P356

Q43292397-1E01141A-14DF-4B6C-AA9F-793D65C36294

P433

Q43292397-77DBCC9A-410A-41FC-831C-5613B29AFAAD

P478

Q43292397-022DDD9A-E597-446F-8AB2-BE0489462927

P577

Q43292397-F0F1594F-C175-4BD8-AFED-3908B2625153

P5875

Q43292397-A3E14164-2776-48D3-BD33-D7FC81750688

P698

Q43292397-FC0E3387-442A-44F7-B6F9-41266E9C20E2

P356

J.JCMG.2009.04.011

P1433

JACC: Cardiovascular Imaging

P1476

Regadenoson induces comparable ...... from the ADVANCE MPI 2 trial.

@en

P2093

Ami E Iskandrian

http://www.w3.org/2001/XMLSchema#string

Ann W Olmsted

http://www.w3.org/2001/XMLSchema#string

Gregory S Thomas

http://www.w3.org/2001/XMLSchema#string

John J Mahmarian

http://www.w3.org/2001/XMLSchema#string

Lemuel A Moye

http://www.w3.org/2001/XMLSchema#string

Manuel D Cerqueira

http://www.w3.org/2001/XMLSchema#string

Robert C Hendel

http://www.w3.org/2001/XMLSchema#string

Timothy M Bateman

http://www.w3.org/2001/XMLSchema#string

P304

959-968

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JCMG.2009.04.011

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2009-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26740586

http://www.w3.org/2001/XMLSchema#string

P698

19679284

http://www.w3.org/2001/XMLSchema#string